TITLE

REKOMBINOWANY AKTYWNY CZYNNIK VII (rVIIa) -- WŁAŚCIWOŚCI FARMAKOLOGICZNE I ZASTOSOWANIE KLINICZNE

AUTHOR(S)
Zubkowicz, Marta; Chojnowski, Krzysztof
PUB. DATE
December 2007
SOURCE
Problemy Terapii Monitorowanej;dec2007, Vol. 18 Issue 4, p245
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Recombinant activated factor VII (rFVIIa; NovoSeven, NovoNordisk, Dennmark) was originally developed for the treatment of patients with haemophilia A and haemophilia B with inhibitory antibodies against factor VIII or factor IX. It has been approved in Europe for the treatment of haemorrhage in inherited factor VII deficiency and Glanzmann's thrombasthenia with platelet antibodies and refractory to platelet transfusions. In recent years, rFVIIa has also been employed for the management of uncontrolled bleeding in a number of congenital and acquired hemostatic abnormalities.
ACCESSION #
29366389

 

Related Articles

  • A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model. Kitazawa, Takehisa; Igawa, Tomoyuki; Sampei, Zenjiro; Muto, Atsushi; Kojima, Tetsuo; Soeda, Tetsuhiro; Yoshihashi, Kazutaka; Okuyama-Nishida, Yukiko; Saito, Hiroyuki; Tsunoda, Hiroyuki; Suzuki, Tsukasa; Adachi, Hideki; Miyazaki, Taro; Ishii, Shinya; Kamata-Sakurai, Mika; Iida, Takeo; Harada, Aya; Esaki, Keiko; Funaki, Miho; Moriyama, Chifumi // Nature Medicine;Oct2012, Vol. 18 Issue 10, p1570 

    Hemophilia A is a bleeding disorder resulting from coagulation factor VIII (FVIII) deficiency. Exogenously provided FVIII effectively reduces bleeding complications in patients with severe hemophilia A. In approximately 30% of such patients, however, the 'foreignness' of the FVIII molecule...

  • Surgery-associated acquired hemophilia A. Theodossiades, G.; Tsevrenis, V.; Nomikou, E.; Dadiotis, L.; Kontopoulou-Griva, I. // Annals of Hematology;Nov2001, Vol. 80 Issue 11, p691 

    We present two patients who acquired factor VIII antibodies in the immediate postoperative period. One patient was receiving warfarin that was temporarily discontinued but reintroduced after the procedure. Preoperatively, none gave a history of bleeding, even with past surgeries, and both had...

  • RECOMBINANT ACTIVATED FACTOR VII: DOES IT HAVE A ROLE IN MANAGEMENT OF SEVERE POSTPARTUM HEMORRHAGE? Shankar, Anand; Jacob, Mathews; Puri, Randhir // Journal of South Asian Federation of Obstetrics & Gynecology;Jan-Apr2011, Vol. 3 Issue 1, preceding p1 

    Postpartum hemorrhage is a leading cause of mortality and morbidity in obstetric patients. Recombinant activated factor VII, a hemostatic agent originally developed for use in patients suffering from hemophilia has been increasingly and successfully used as an off-label therapy in patients of...

  • Inhibitor development in two patients with mild haemophilia A - spontaneous disappearance and no recurrence of the inhibitor after re-challenge. Reitter-Pfoertner, Sylvia; Horvath, Birgit; Lechner, Klaus; Sunder-Plassmann, Raute; Mannhalter, Christine; Pabinger, Ingrid // Wiener Klinische Wochenschrift;Mar2012, Vol. 124 Issue 5/6, p198 

    Inhibitors against factor VIII (FVIII) complicate the treatment of patients with haemophilia. In mild haemophilia, the development of antibodies against FVIII is rare. However, the occurrence of an inhibitor in mild haemophilia changes the bleeding phenotype from mild to severe, and thus becomes...

  • Acquired Hemophilia A: A Frequently Overlooked Autoimmune Hemorrhagic Disorder. Yoshihiko Sakurai; Tomohiro Takeda // Journal of Immunology Research;2014, p1 

    Acquired hemophilia A (AHA) is a rare hemorrhagic disease in which autoantibodies against coagulation factor VIII- (FVIII-) neutralizing antibodies (inhibitors) impair the intrinsic coagulation system. As the inhibitors developed in AHA are autoantibodies, the disease may have an autoimmune...

  • Ongoing NovoSeven trials. Erhardtsen, Elisabeth // Intensive Care Medicine;Oct2002 Supplement 2, Vol. 28, pS248 

    Recombinant activated factor VII (rFVIIa, 'NovoSeven' was initially developed for the treatment of bleeding in patients with haemophilia and inhibitors, and is currently licensed in most countries worldwide. The mechanism of action suggests that its enhancing effects in haemostasis are limited...

  • Intracerebral hemorrhage: natural history and rationale of ultra-early hemostatic therapy. Mayer, Stephan A. // Intensive Care Medicine;Oct2002 Supplement 2, Vol. 28, pS235 

    Stroke is a major health problem worldwide, causing high morbidity and mortality. Intracerebral hemorrhage (ICH) accounts for 15% of stroke cases in the US and Europe and up to 30% in Asian populations. It is less treatable than other forms of stroke and causes higher morbidity and disability....

  • Novel Gene Therapy May Lead to Cure in Hemophilia A Patients, Even Hard-to-Treat Subset Requiring Expensive Treatment.  // Ascribe Newswire: Medicine;7/3/2006, p6 

    The article discusses the novel gene therapy that may lead to cure in hemophilia A patients. The discovery was made by the Medical College of Wisconsin and BloodCenter of Wisconsin researchers in Milwaukee. The study of genetically altered hemophilia mice is published in the July 2006 edition of...

  • Lentiviral Vector Platform for Production of Bioengineered Recombinant Coagulation Factor VIII. Spencer, H. Trent; Denning, Gabriela; Gautney, Richard E.; Dropulic, Boro; Roy, Andre J.; Baranyi, Lajos; Gangadharan, Bagirath; Parker, Ernest T.; Lollar, Pete; Doering, Christopher B. // Molecular Therapy;Feb2011, Vol. 19 Issue 2, p302 

    Patients with hemophilia A present with spontaneous and sometimes life-threatening bleeding episodes that are treated using blood coagulation factor VIII (fVIII) replacement products. Although effective, these products have limited availability worldwide due to supply limitations and product...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics